{"id":"NCT04757376","sponsor":"Celltrion","briefTitle":"A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis","officialTitle":"A Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-06-17","primaryCompletion":"2023-05-18","completion":"2023-11-16","firstPosted":"2021-02-17","resultsPosted":"2024-05-16","lastUpdate":"2024-06-14"},"enrollment":479,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Women With Osteoporosis"],"interventions":[{"type":"BIOLOGICAL","name":"CT-P41","otherNames":[]},{"type":"BIOLOGICAL","name":"US-licensed Prolia","otherNames":[]}],"arms":[{"label":"CT-P41","type":"EXPERIMENTAL"},{"label":"US-licensed Prolia","type":"ACTIVE_COMPARATOR"}],"summary":"This study is a Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteoporosis","primaryOutcome":{"measure":"Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 - Full Analysis Set (FAS)","timeFrame":"baseline (screening), Week 52 predose","effectByArm":[{"arm":"CT-P41","deltaMin":4.9597,"sd":0.29977},{"arm":"US-licensed Prolia","deltaMin":5.1528,"sd":0.32133}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"50 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":20,"countries":["Estonia","Latvia","Poland","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":239},"commonTop":["Upper respiratory tract infection","COVID-19","Arthralgia","Nasopharyngitis","Vitamin D deficiency"]}}